As a mother of a son (age 11) who has been dealing with this allergy combo. since one, I agree with this article. We also have contact and air borne to same which just adds to it all. The important thing to remember is to read, read and read and know about everything that goes into your child's mouth. Cooking things at home is major too. My dream is that they will find a cure to all food allergies and to find resturants that actually can come up with something for my child to eat besides...
DBV Technologies, a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for its investigational Viaskin® Peanut immunotherapy for the treatment of peanut-allergic children ages 4 to 11 years. Viaskin Peanut is the Company’s lead product candidate designed to potentially reduce the risk of life-threatening allergic reactions due to accidental exposure to peanuts.
Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
This free two-page handout is filled with essential information about anaphylaxis, a severe allergic reaction that can be life-threatening. Symptoms of Anaphylaxis Being Prepared for Anaphylaxis Common Causes of Anaphylaxis Knowing How to Treat...
On June 11, 2019, in Oakland, California, the Institute for Clinical and Economic Review (ICER) and its California Technology Assessment Forum (CTAF) met to assess the clinical effectiveness and value of treatments for peanut allergy. The review examined two new technologies to induce immune tolerance — Viaskin® Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) — as well as non-commercialized oral immunotherapy (OIT).
The Asthma and Allergy Foundation of America (AAFA) addresses concerns regarding the Final Evidence Report assessing the clinical effectiveness and value of treatments for peanut allergy released by the Institute for Clinical and Economic Review (ICER) on July 10, 2019. ICER’s report may cause concern for the allergy community that the findings will restrict access to new treatments for peanut allergy.
On Jan. 31, 2020, the U.S. Food and Drug Administration (FDA) announced its approval of Aimmune Therapeutics’ peanut treatment, Palforzia, for children ages 4 to 17. This is big news for the food allergy community. Food allergies put a significant mental, social and financial burden on families. Until now, strict avoidance has been the only way to avoid allergic reactions. Palforzia may give many families managing peanut allergies more freedom and greater quality of life.
New research suggests that giving antihistamine medicine to a child experiencing anaphylaxis--a sudden and severe allergic reaction that can quickly be fatal--usually does more harm than good by delaying emergency treatment.
While experimental desensitization strategies are available in research settings, people with food allergies must avoid known allergens and are advised to carry injectable epinephrine to prevent potentially life-threatening allergic reactions caused by accidental exposures. To help alleviate this risk, a new study to evaluate an experimental treatment for food allergy launched today.
DBV Technologies, a clinical-stage biopharmaceutical company, today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin® Peanut for the treatment of peanut-allergic children ages 4 to 11 years.
The Asthma and Allergy Foundation of America (AAFA) recently exhibited at the 2019 American Academy of Pediatrics (AAP) conference. We learned the latest news in pediatrics and food allergies. We also spoke with doctors about the food allergy and asthma programs and services we offer. Kids With Food Allergies (KFA) is a division of AAFA.
On Sept. 13, 2019, the U.S. Food and Drug Administration’s (FDA) Allergenic Products Advisory Committee recommended the approval of Aimmune Therapeutics’ peanut treatment, Palforzia. If approved, Palforzia would be ground-breaking for the future of food allergy treatments. What Is Palforzia? Palforzia, also known as AR101, is a type of oral immunotherapy (OIT) for peanut allergy. If approved, it would be the first FDA-approved treatment for peanut allergy. Currently, some allergists already...
Press Release: Consortium of Food Allergy Research Completes Recruitment of NIH-sponsored CoFar6 Phase II Trial with DBV's Viaskin(r) Peanut in Treatment of Peanut Allergy Leading US centers in food allergy involved in an NIH-funded CoFAR6 study,...
A report from NBCNews explains two new treatments being studied: multiple food oral immunotherapy and a new skin patch. The treatments involve exposing the patient to a small amount of their allergen and slowly increasing the dose to build up...
AAFA is working with researchers at Northwestern University who are currently conducting a pilot study called "Parental Therapy Preferences for Children with Food Allergy". Parents of children with food allergies are invited to complete an online survey about your thoughts on possible food allergy treatments. This study aims to better understand the needs of patients and their families when deciding on a therapy in order to improve current and future therapy options. All responses will be...
On Aug. 21, 2019, Kenny Mendez, President and CEO of the Asthma and Allergy Foundation of America (AAFA), co-hosted a Facebook Live session with blogger Anna Luther of My Life and Kids. If you didn’t have a chance to tune in live, you can watch a replay of session. (Kids With Food Allergies is a division of AAFA.)
On July 25, 2019, Kenny Mendez, President and CEO of the Asthma and Allergy Foundation of America (AAFA), co-hosted a Facebook Live session with pediatrician and blogger, Dr. Katie Freidman of Forever Freckled. If you didn’t have a chance to tune in live, you can still watch the session.
On Sept. 26, 2019, Kenneth Mendez, CEO and president of the Asthma and Allergy Foundation of America (AAFA), co-hosted a Facebook Live session with blogger Deva Dalporto of MyLifeSuckers. If you didn’t have a chance to tune in live, you can watch a replay of session. Kids With Food Allergies (KFA) is a division of AAFA.
DBV Technologies, a clinical-stage biopharmaceutical company, today announced positive topline results of the three-year, open-label extension of the Phase III PEPITES trial (PEOPLE) evaluating the long-term efficacy and safety of investigational Viaskin® Peanut in peanut-allergic children ages 4 to 11 years. The results demonstrate long-term clinical benefit as shown by an increase in eliciting dose (ED), which may decrease the chance of reacting to an accidental peanut exposure.
The final research results for a new treatment for protection against accidental exposure to peanut was presented today at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting and published in the New England Journal of Medicine. The results show it is possible for some people with peanut allergy to protect themselves from accidental ingestion by building up their tolerance to peanut over time.
The future of food allergy: developing new treatments by Michael H. Land, MD FAAAAI I'm the father of a food allergic child. If you're reading this, I am guessing you or someone close to you has a food allergy. The minute you found out...
BlueWillow Biologics®, a clinical-stage biopharmaceutical company, today announced it has been awarded a Fast-Track Small Business Research Innovation (SBIR) contract from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of an intranasal therapeutic peanut allergy vaccine using the company’s NanoVax® platform.
This gives me hope that my child will eventually be allergy free and his life will not be in danger from a simple item of food! Thank you so much for this great article in layman terms so that we parents can understand it!
Hi Michael, Very interesting for us to read as I have more than one grandchild with food allergies! Congratulations on all your accomplishments and studies. Love from us all, your old Oxford neighbour!
Welcome Jessica & Sandra! We are glad you found KFA. We hope you will join us on our Support Forums. We have several forums that may be of interest. Main Forum Babies, Toddlers & Preschoolers We even have a new forum for saving money! http://community.kidswithfooda...s-for-food-allergies We have a fantastic Food & Cooking forum Don't forget to check out our recipe section! Come join us! .
This is great news! I have a 17-year old with a peanut allergy, but I see this was tested only on younger kids. Will this be potentially tested/available for older kids/adults as well? Also, any thoughts/ideas at all on when this will be through testing and approval and available for the general peanut-allergic population?
Hi, Carolyn ... there is a lot of exciting research into immunotherapy right now. For instance, the FDA is now considering the immunotherapy drug Palforzia for children and teens with peanut allergy. And research has been ongoing with drugs like Viaskin. I have much hope that families managing food allergies will have many additional tools in their kit in the future. In the meantime, how can our community help you and your teen?
Thanks for the response. I Googled Palforzia and a link came up to a recent article in the Atlantic (9/13/09) stating this "drug" is nothing but peanut flour in a capsule, with an estimated cost of $4200/year!...and the need for the patient to take it indefinitely. Even if it reliably worked (not proven per the article), it just also seems like another way for the pharmaceutical industry to rip off families of allergic kids (Epi-pen exorbitant costs, case in point).
It makes me so happy to read about positive results on treating people with a peanut allergy. My grandson is 10 now...and I am sometimes gripped with fear regarding his allergy. I am so hoping that a real cure is on the horizon...for him and for all of those dealing with this. Thanks for all you do to keep us informed.
We are guilty of doing just this when my then 10 mo old granddaughter was given sunflower butter for the first time. We didn’t immediately recognize that she was going into anaphylactic stage, so we gave her benedryl. Then she started coughing, vomiting and diarrhea, then we called 911 and administered the Epipen. Ambulance came and they ended up giving her two more, then once at the hospital, she received yet another two, along with steroids. She was kept overnight. The second time she...
My son has been prescribed to take antihistamines on a daily basis because he has ideopathic anaphylaxis. I give him Zyrtec and Allegra daily, and from what I have read, this is the protocol for a person who has ideopathic anaphylaxis. I was guilty of doing the same thing before we actually knew he was having anaphylactic reactions though. What has complicated things for us, is that I share 50/50 custody of my son with my ex-husband, who was not on board with giving our son these daily...
At only 8 years old, Anthony is on the cutting edge of science. He is in a clinical trial for food allergy research and shares his story to help Kids With Food Allergies (KFA). Anthony has multiple food allergies. He’s allergic to barley, wheat, eggs, tree nuts, and peanuts. By the time he reached age 4, he had been hospitalized three times because of allergic reactions. “Trying to imagine a ‘normal life’ for him through these challenges was difficult,” his mom, Kelli, said. “There were...
The Asthma and Allergy Foundation of America (AAFA) and MedicAlert have teamed up to help you manage your child’s food allergies and prevent severe allergic reactions. (Kids With Food Allergies is a division of AAFA). We’re asking you to “ACT” to manage your child’s allergies: “A” means have an action plan for anaphylaxis. “C” reminds you to carry important medicines and have your child wear a medical ID to alert others of their condition. “T” calls for having a treatment plan that includes...
The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch. The FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis—commonly known as allergies—for adults and children six years of age and older.
Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today announced the publication of a longitudinal analysis that explored the safety, efficacy and food allergy-related quality of life of long-term treatment with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp, previously known as investigational agent AR101] in patients with peanut allergy.
COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for evaluation of COUR's CNP-201 in a proof-of-concept (Phase 1 / 2) study in people who are allergic to peanuts.
When you block a person, they can no longer invite you to a private message or post to your profile wall. Replies and comments they make will be collapsed/hidden by default. Finally, you'll never receive email notifications about content they create or likes they designate for your content.
Note: if you proceed, you will no longer be following .